Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLM101 in PMM2-CDG
NCT05549219Phase 2Completed
- Sponsor
- Glycomine
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 3
01
Overview
A Phase 2 trial of GLM101 in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), sponsored by Glycomine. Started Nov 2022; status: completed.
02
Drugs
GLM101
03
Conditions
phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)
Beyond the preview
Go deeper on NCT05549219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549219.